



# Roche SARS-CoV-2 Rapid Antigen Testing Portfolio & Emerging Virus Variants

Roche has conducted sequence analyses in collaboration with our partner, SD Biosensor, as well as wet testing (conducted by SD Biosensor) to evaluate the potential impact of the SARS-CoV-2 variants, including the SARS-CoV-2 variants of concern - **Alpha** (B.1.1.7 lineage); **Beta** (B.1.351 lineage), **Gamma** (P.1 lineage) and **Delta** (B.1.617.2 lineage) - on the SARS-CoV-2 Rapid Antigen Test, SARS-CoV-2 Rapid Antigen Test Nasal, and the SARS-CoV-2 Antigen Self Test Nasal.



No impact of the following virus variants has been observed on the Roche SARS-CoV-2 Rapid Antigen Testing Portfolio:

Country first reported in	WHO Nomenclature	WHO Classification	Lineage
UK	Alpha	VOC	B.1.1.7
South Africa	Beta	VOC	B.1.351
Japan/Brazil	Gamma	VOC	P.1
India	Delta	VOC	B.1.617.2
Peru	Lambda	VOI	C.37
Colombia	Mu	VOI	B.1.621
India	Kappa	VUM	B.1.617.1
	N/A		B.1.617.3
	Delta Plus		AY.1
	Delta Plus		AY.2
	Delta Plus		AY.3
USA	Epsilon	VUM	B.1.427

Country first reported in	WHO Nomenclature	WHO Classification	Lineage
USA	Epsilon	VUM	B.1.429
	Iota	VUM	B.1.526
			B.1.526.2
Egypt	N/A		C.36
Colombia	Mu		B.1.621
Brazil	Zeta		P.2
Multiple countries	Eta	VUM	B.1.525
Phillipines	Theta		P.3
UK			A.23.1
France			B.1.616
Russia			AT.1

VOC: Variant of Concern, VOI: Variant of Interest, VUM: Variant Under Monitoring

As emerging virus variants are identified, we commit to continuously monitor them independently and in collaboration with our partner, SD Biosensor.

## References

- 1) SD Biosensor, Analytical Study (in-silico testing): Q COVID-19 Ag\_SARS-CoV-2 Variants in-silico analysis\_Rev.03
- 2) SD Biosensor, Analytical Study (wet testing): SARS-CoV-2 Variants LOD test as recombinant protein\_Rev.06